OFFERING KNOWLEDGE AS A SERVICE - A TAXONOMY OF KNOWLEDGE-INTENSIVE BUSINESS SERVICES

Servitization describes the transformation of a manufacturer to a customer-centric service and solution provider. Providing customer solutions requires the integration of knowledge from different domains, e.g., engineering, software, and service, and usually also entails that more knowledge-intensive business services (KIBS) become part of the manufacturer’s overall business model. Against this background, this article investigates how manufacturing and software firms leverage knowledge in KIBS and corresponding business models. We developed a taxonomy that systematizes KIBS along the three meta-dimensions of value proposition, value creation, and value capture. The application of our taxonomy to exemplary cases from both industries shows different strategies of knowledge usage across these industries. Our findings can support the development of KIBS and help practitioners to understand different ways of utilizing knowledge as a strategic resource. Implications for research point to the need for better understanding the collaboration of multiple actors from a knowledge-based perspective

Algorithmic Management: Eight Problems but Human-Centrism Ain\u27t One

Algorithmic Management (AM) is an emerging topic that is used to control the workforce on on-demand platforms (ODPs). Although widely utilized, AM is contested among practitioners and researchers. Therefore, the expansion of ODPs controlled by AM requires an exploration of appearing problems in this system. The paper aims to examine the interrelated problems associated with the use of AM for regulation, in addition to the complex communication structures and data processes. Derived from a systematic literature review, this research provides a broad perspective on the problems existing in AM-supported on-demand platform (ODP) ecosystems. Eight interrelated problem categories associated with current practices in AM alongside the communication streams in ODP ecosystems have been identified, revealing potential for optimization. Furthermore, the potential role and responsibility of human managers is considered in fostering human-centric AM, providing directions for future research

Integrierte Geschäftsmodell- und Arbeitsgestaltung für die Bereitstellung und Vermarktung von Service-Wissen

Die durch kleine und mittelständische Unternehmen geprägte Investitionsgüterindustrie steht aufgrund der zunehmenden Internationalisierung im Servicegeschäft vor großen Herausforderungen. Mitarbeiterengpässe, hohe Prozesskosten und unzureichendes Wissensmanagement machen den Service zur potenziellen betriebs- und volkswirtschaftlichen Wachstumsbremse. Durch die Digitalisierung entstehen aber auch große Nutzenpotenziale im Servicegeschäft. Ziel des im Projekt SerWiss entwickelten integrierten Ansatzes ist es, kleine und mittelständische Anbieter von Investitionsgütern zu befähigen, Servicewissen auf der Basis eines digitalen Lösungsansatzes unter Gewährleistung einer humanen Arbeitsgestaltung effizient zu generieren, zu strukturieren und international bereitzustellen bzw. zu vermarkten

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health